Clinical trials: Ultra-high Risk for Psychosis
Clinical High Risk for Psychosis (CHR)
French Validation of Schizophrenia Proneness Instrument- Child Youth
The clinical concept of a at risk mental state of developing psychosis is based on the identification of attenuated psychotic symptoms during the prodromal phase of psychoses (Schmidt et al., 2015).
- Trial name
- SPI-CY-Fr (NCT06649552)
- Testing
- Psychiatric and psychological diagnostic tests
- Where
- 3 sites in France
- Volunteers
- 52 people
- Sponsor
- Centre Psychothérapique de Nancy
Psychotic Disorders, Personality Disorders
The Staged Treatment in Early Psychosis Study
A sequential multistage randomised clinical trial (SMART) to produce evidence to guide a step-wise clinical approach for the treatment of ultra high risk patients and reduction of risk for psychosis and other deleterious clinical…
- Conditions
- Psychotic Disorders, Personality Disorders, Clinical High Risk
- Trial name
- STEP (NCT02751632)
- Testing
- Support and Problem Solving Therapy, Cognitive Behavioural Case Management, Fluoxetine
- Where
- 5 sites in Australia
- Volunteers
- 342 people
- Sponsor
- Orygen
Clinical High Risk for Psychosis (CHR)
Efficacy of Mindfulness in PREventing Progression to Psychosis in Individuals With an Ultra High Risk for Psychosis
The main objective is to evaluate the efficacy of a group-based mindfulness therapy programme in reducing distress associated with symptoms of UHR (Ultra High Risk) or FEP (first psychotic episode) compared with usual treatment.
- Trial name
- EM-PREPS (NCT06870305)
- Testing
- MBTP : Mindflulness based training for psychosis
- Where
- 2 sites in France
- Volunteers
- 270 people
- Sponsor
- Centre Psychothérapique de Nancy
Ultra High Risk for Psychosis
Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe
The purpose of this study is to determine whether omega-3 fatty acids are effective in the prevention of psychosis in individuals at ultra-high risk for psychosis.
- Trial name
- PURPOSE (NCT02597439)
- Testing
- Omega-3 fatty acids
- Where
- 14 sites in Austria, Germany and 7 more
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Rene Kahn
Schizophrenia
Study on Predictiors and Mechanism of Conversion to Psychosis in Individuals at Ultra-high Risk Group
Considering the complex pathological mechanism and the poor treatment outcomes of schizophrenia, early detection and intervention gradually become the key work for the foundational and clinical research in schizophrenia.
- Trial name
- NCT03965598
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Second Xiangya Hospital of Central South University
Clinical High Risk for Psychosis, Ultra High Risk for Psychosis
Sacramento Clinical High Risk for Psychosis Stepped-Care Program
This is a dissemination and implementation study that is evaluating a stepped-care intervention for identifying and treating youths at clinical high-risk for psychosis within multiple community mental health centers.
- Trial name
- SCIP Step (NCT06640803)
- Testing
- Stepped-Care including Cognitive Behavioral Case Management
- Where
- 6 sites in United States
- Volunteers
- 223 people
- Sponsor
- University of California, Davis
Emotional Dysfunction, Psychosis
Application of UP for Transdiagnostic Treatment of Emotional Disorders for UHR for Psychosis Patients
The principal aim of the study is to assess the efficacy of the Unified Protocol (UP) for the treatment of the comorbid symptomatology of patients with Ultra High Risk (UHR) for psychosis.
- Trial name
- NCT04929938
- Testing
- Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
- Where
- 2 sites in Spain
- Volunteers
- 42 people
- Sponsor
- Fundació Sant Joan de Déu
Clinical High Risk for Psychosis, Ultra High Risk for Psychosis
Endocannabinoid Activity Remodulation for Psychosis Liability in Youth
Clinical High-Risk (CHR) for Psychosis is characterized by the occurrence of unusual stressful experiences (attenuated psychotic symptoms, APS), anxious symptoms, psychological distress, and substantial impairment of the…
- Conditions
- Clinical High Risk for Psychosis, Ultra High Risk for Psychosis, Attenuated Psychotic Symptoms
- Trial name
- EARLY (NCT06037993)
- Testing
- Ultra-micronized Palmitoylethanolamide (PEA)
- Where
- 2 sites in Italy
- Volunteers
- 20 people
- Sponsor
- University of Udine
Ultra-high Risk for Psychosis, Clinical High Risk for Psychosis
Metacognitive Training in Ultra-high Risk
The aim of this pilot study is to examine whether metacognitive training can improve symptoms, wellbeing and functioning in individuals with attenuated psychotic symptoms.
- Conditions
- Ultra-high Risk for Psychosis, Clinical High Risk for Psychosis, At-risk Mental State
- Trial name
- NCT05827900
- Testing
- Metacognitive Training
- Where
- 2 sites in Austria
- Volunteers
- 30 people
- Sponsor
- Medical University of Vienna
Psychosis
E-Detection Tool for Emerging Mental Disorders
Psychosis is a severe mental disorder that involves abnormal experiences and altered behaviour. Although the onset of psychosis occurs in young people, most cases will only be identified later in the course of illness.
- Trial name
- ENTER (NCT05127278)
- Where
- 2 sites in United Kingdom
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- King's College London
Attenuated Psychosis Syndrome
Exercise and Markers of Medial Temporal Health in Youth At-risk for Psychosis
The goal of this proposal is to test the feasibility and effectiveness of cardiovascular exercise in promoting brain health and improving related symptoms (e.g., hearing sounds that are not there, feeling emotionally detached…
- Trial name
- NCT02155699
- Testing
- Exercise 1, Exercise 2
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Boulder
Schizophrenia, Psychoses
Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis
The study will provide an empirical basis for a pharmacological treatment option. An open-label, randomized, multi-centre parallel group design is used.
- Trial name
- NCT00204061
- Testing
- Supportive management, Amisulpride
- Where
- Germany
- Volunteers
- 124 people
- Sponsor
- University of Cologne
Schizophrenia, Prodrome
Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis
Early intervention in psychosis might be associated with better outcomes. However, intervention in the pre-psychotic phase has been questioned as, using current criteria, only 20-50% of individuals classified as prodromal develop…
- Trial name
- NCT00396643
- Testing
- Omega 3 fatty acids
- Where
- Austria
- Volunteers
- 81 people
- Sponsor
- Medical University of Vienna
Schizophrenia
Effectiveness of Neuroadaptive Cognitive Training in Adolescents at Risk for Psychosis
This study will evaluate the effectiveness of intensive computerized cognitive training in preventing the onset of psychotic disorder and improving adaptive functioning in adolescents at high risk of schizophrenia.
- Trial name
- NCT00655239
- Testing
- Neuroadaptive cognitive training, Computer games
- Where
- United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco